Hulskof schreef op 12 december 2022 20:40:
www.evaluate.com/vantage/articles/eve...Those MD Anderson data featured at Ash on Saturday, and comprised 41 patients, all of whom were refractory to or intolerant of Seagen’s Adcetris. Initial responses across all doses were 93% overall, with a 66% rate of complete remissions.
However, here too AFM13 faces durability questions. The data were split into 19 patients who had received two cycles of therapy, and 22 who had received up to four cycles, and only four of the 10 complete responders seen in the former group were still in remission at 12 months – two having received stem cell transplants.
Meanwhile, most of the remissions seen in the second group are ongoing, but are of short duration. “When we go up to four cycles we’re hoping that duration of responses will increase,” said the presenting investigator, Dr Yago Nieto.
Er lijkt dus ook met de NK-combi een probleem met duurzaamheid. Dat verklaart ws nog het meest de grote afstraffing.